Abstract:Heat shock protein 90 (HSP90) plays a crucial role in cancer cell growth and metastasis by stabilizing overexpressed signaling proteins. Inhibiting HSP90 has emerged as a promising anti -cancer strategy. In this study, we aimed to develop and characterize a HSP90-targeted molecular imaging probe, [ 64 Cu]Cu-DOTA-BDA-GM, based on a specific HSP90 inhibitor, geldanamycin (GM), for PET imaging of cancers. GM is modified at the C-17 position with 1,4-butane-diamine (BDA) and linked to 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for 64 Cu radiolabeling. We evaluated the probe's specific binding to HSP90-expressing cells using Chinese hamster ovary (CHO) cells and breast cancer cells including MDA-MB-231, MDA-MB-435S, MCF7, and KRBR -3 cell lines. A competition study with non -radioactive GM-BDA yielded an IC50 value of 1.35 +/- 0.14 nM, underscoring the probe's affinity for HSP90. In xenograft models of MDA-MB-231 breast cancer, [ 64 Cu]Cu-DOTA- BDA-GM showcased targeted tumor localization, with significant radioactivity observed up to 18 h postinjection. Blocking studies using unlabeled GM-BDA and treatment with the anticancer drug Vorinostat (SAHA), which can affect the expression and activity of numerous proteins, such as HSPs, confirmed the specificity and sensitivity of the probe in cancer targeting. Additionally, PET/CT imaging in a lung metastasis mouse model revealed increased lung uptake of [ 64 Cu]Cu-DOTA-BDA-GM in metastatic sites, significantly higher than in non -metastatic lungs, illustrating the probe's ability to detect metastatic breast cancer. In conclusion, [ 64 Cu] Cu-DOTA-BDA-GM represents a sensitive and specific approach for identifying HSP90 expression in breast cancer and metastases, offering promising implications for clinical diagnosis and monitoring.

Discovery of Diamine-Linked 17-Aroylamido-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Synthesis and Preliminary Antitumor Activity Evaluation of 17-(5-(substituted Cinnamamido)pentylamino)-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Design, Synthesis and Biological Evaluation of 17-Arylmethylamine-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.

In Vitro and in Vivo Evaluation of 17-Phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

Synthesis of Novel 17-[3,6-dioxa-8-n-(substituted Cinnamyol)-Octanediamino]-17-demethoxygeldanamycin Derivatives

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation

Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy

SNX-25a, a Novel Hsp90 Inhibitor, Inhibited Human Cancer Growth More Potently Than 17-AAG.

Discovery of 18Β-Glycyrrhetinic Acid Conjugated Aminobenzothiazole Derivatives As Hsp90-Cdc37 Interaction Disruptors That Inhibit Cell Migration and Reverse Drug Resistance

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors

Study on Geldanamycin of Promoting Heat-Induced Cell Killing of Cervix Cancer HeLa Cells

Design, Synthesis and Pharmacological Evaluation of 4,5-Diarylisoxazols Bearing Amino Acid Residues Within the 3-Amido Motif As Potent Heat Shock Protein 90 (hsp90) Inhibitors

Synthesis and Characterization of 64Cu-Labeled Geldanamycin Derivative for Imaging HSP90 Expression in Breast Cancer

Geldanamycin, a Heat Shock Protein 90‐binding Agent, Disrupts Stat5 Activation in IL‐2‐stimulated Cells

Synthesis of C3′‐Foused Aryl/Penta‐1,4‐dien‐3‐one/Amine Hybrids as HSP90 C‐Terminal Inhibitors

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry

Design, Synthesis, and Biological Evaluation of Truncated Deguelin Derivatives As Hsp90 Inhibitors